

ROLE OF EUROPEAN CANCER LEAGUES IN PROMOTING AWARENESS OF EARLY DETECTION

FOCUS ON ORGANISED CANCER SCREENING IN EUROPE

DAVID RITCHIE, ASSOCIATION OF EUROPEAN CANCER LEAGUES (ECL)

DECLARATION OF INTEREST

ECL receives an Operating Grant from the European Commission under the Third EU Health Programme 2014-2020:

FPA 2014 (664682)
FPA 2017 (785273)



Co-funded by the Health Programme of the European Union

• ECL is supported by L'Oréal Garnier through an unrestricted educational grant.

ABOUT ECL



Founded in 1980

- 26 members in 23 countries in WHO Europe region
- + 3 members joining in 2019
 - AECC (ES), CRUK, O FONDS (LV)
- Mission: "Europe free of cancer"

ECL STRATEGY 2019-2021

6 Goals

- I. Influence Cancer Control Policies
- 2. Promote Cancer **Prevention**
- 3. Enhance Access to Cancer **Screening** and Early Diagnosis
- 4. Ensure Equal Access to High Value Cancer Treatments for all Cancer Patients in Europe
- 5. Develop Actions Supporting Cancer **Patients**, Survivors and Caregivers
- 6. Grow Membership and Increase Impact of ECL in Europe



OVERVIEW OF ACTIVITIES



EUROPEAN CODE AGAINST CANCER



EUROPEAN CODE AGAINST CANCER WORKSHOP, BELFAST & DUBLIN, 2019

BEATING CANCER: MISSION POSSIBLE TOWARD EFFECTIVE CANCER CONTROL IN EUROPE in at Cancer Manifesto

MEPs AGAINST CANCER (MAC) EUROPEAN 2019 ELECTIONS MANIFESTO

III. IMPROVING CARE AND INVOLVING PATIENTS IN HEALTH POLICY DECISIONS

There are around 10 million people with a history of cancer in Europe. Given this large (and growing) number of cancer patients and survivors, focusing on their qualityof-life is fundamental. Moreover, patient voice shall be appropriately represented in the decision-making process related to national and European health policies.

New diagnostic tools and treatments such as biological antibody medicines, enabled that many cancer cases today can be diagnosed earlier, treated more effectively or even cured altogether. However, in Europe, there are substantial differences in access to new cancer treatments and their added value to the patient has often been uncertain.

II. BEATING CANCER WITH HIGH QUALITY **TREATMENTS**

Support legislation protecting for cancer

patients, survivors and caregivers, particularly in access to financial services and at in their employment.



Calling for integration for rehabilitation, psychosocial and palliative care in European healthcare services:



Making patient voice heard in European and national decision-making.

I. PREVENTION AS A KEY TO SUSTAINABLE CANCER CONTROL

Up to 50% of cancer deaths in Europe could be prevented if current knowledge about cancer prevention was put into practice.

Address the determinants of health at the individual and community level by influencing demand, access and affordability of tobacco, alcohol and foods and drinks high in saturated fats, trans fats, salt and sugar;



Promote access to quality assured cancer screening and early detection services, supporting Member States in the implementation of cancer screening guidelines and working with the WHO towards the elimination of cervical cancer:

Take action to reduce harmful occupational and environmental exposures, concentrating on reduction of carcinogens and mutagens. and addressing impacts of air quality and climate change.

BEATING CANCER: MISSION POSSIBLE

TOWARDS EFFECTIVE CANCER CONTROL IN EUROPE



MEPs Against Cancer 2019 European Elections Manifesto



Ensuring equal access to high quality treatments set at fair prices which are both sustainable and profitable enough to steer innovation:



Boosting international cooperation in cancer research, including increased public investments in areas of high unmet medical need and support for open science;



Increasing demand for high standards of evidence before and after treatment approvals, focusing on improved quality of life of cancer patients.

ECL First Screening Workshop

Hosted by the Romanian Cancer Society and national partners

Promoting and embedding the European Code Against Cancer within Screening Programmes:

current status and future perspectives





he Health Pregramme e Furenzan Unine



Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte International Agency for Research on Cancer

World Health Organization





6-7 May 2019 **Bucharest**, Romania

CANCER SCREENING WORKSHOP, BUCHAREST, 2019

2003

L 32	27/34 EN Official Journal of	the Euro	pean Union 16.12.2003		
	COUNCIL REC	out	DATION		
	of 2 Dec				
	on cance				
	on cance	1 Screen	my		
	(2003	(878/EC)			
Havi	COUNCIL OF THE EUROPEAN UNION, ing regard to the Treaty establishing the European Com- tity, and in particular Article 152(4), second subparagraph, cof,	(5)	Additionally, these recommendations are based on the Recommendations on cancer screening of the Advisory Committee on Cancer Prevention together with the ender the Europe against Cancer programme where European collaboration has helped, for example, high quality cancer screening programmes to provide efficient European collections of best practice and to provide efficient European collections of best practice and to provide efficient		
Havi	ing regard to the proposal from the Commission,		population from poor quality screening.		
	ing regard to the opinion of the European Parliament,	(6)	Important factors which have to be assessed before population-wide implementation is decided upo nclude, intr ali, the frequency and interval of the appl cation of the screening test as well as other national or regional epidemiological aspecificities.		
(1)	Article 152 of the Traty provides that Community action is to complement national policies and be directed towards improving public health, preventing human illness and dessess, and obviring sources of danger to human health. Such action shall cover the fight against the major health sources, by promoting research into their causes, their transmission and their prevention, as well as health information and education. Community action in the field of public health shall fully respect the responsibilities of the healthe Statis for the organisation and achiever of health services and metical care.	Ø	Screening allows detection of cancers at an early stage of invasiveness or possibly even before they become inva- sive. Some leasing can have be treated more effectively and the patients can expect to be careful. The main indi- disease-specific mortality. As in the case of certical cancer, cancer precenters are detected, as reduction in cervical cancer incidence can be considered a very helpful indicator.		
(2)	Further development of cancer screening programmes should be implemented in accordance with national law and national and regional responsibilities for the organi- sation and delivery of health services and medical care.	(8)	Evidence exists concerning the efficacy of screening for breast cancer and colorectal cancer, derived from rando- mised trials, and for cervical cancer, derived from obser- vational studies.		
(3)	Cancer is a major disease and cause of death throughout Europe, including the future Member States. An esti- mated number of 1580 096 new cancer cases, excluding non-melanoma sidin cancer, occurred in the European (Inion 1998, 60 these, 1748 were cervical cancers, 11% breast cancers, 14% colorestal cancers and 9% prostest cancers. Fervice and breast cancer constituted 3% and 29%, respectively, of new cancers initiated 3% and 29%, respectively, of new cancers cancers in men.	(9)	Screening is, however, the testing for diseases of people for which no symptoms have been detected. In addition to its beneficial effect on the disease-specific mortality screening population. Healthear providers should be aware of all the potential heardits and risks of screening for a given cancer site before embraining on new popula- tion-based cancer screening programmes. Furthermore, to additional cancer screening programmes, for thermore, meet to be proceeding in any that allows individual citizenes resent to accide on participation in the screening programmes for themselves.		
(4)	Principles for screening as a tool for the prevention of chronic non-communicable diseases were published by				

intuppes to accurate g a 4 toos nor the prevention to by Nordel Teamore, and the prevention of the Nordel Teamore, and the prevention of the Nordel Teamore, and the the Nordel Teamore, and the the Nordel Teamore, and the the same reventing fields, the basis for the present recomnerlations. <image>

Cancer Screening in the European Union (2017)

> Report on the implementation of the Council Recommendation on cancer screening

?

2023

3rd implementation report & update of Council Recommendation

ROADMAP TOWARDS THE THIRD IMPLEMENTATION REPORT ON CANCER SCREENING IN THE EU

TOGETHER WE COULD IMPROVE BREAST SCREENING


You can join MyPeBS, a unique trial on personalized breast cancer screening



COMMUNICATION TO GENERAL PUBLIC




Breast Screening





Personalising Breast Screening

OVERVIEW



SURVEY MEMBERS

8 RESPONSES / 26 MEMBERS JUNE 2019 Forsíða / English

Welcome to our clinic

The Icelandic Cancer Society offers systematic screening for breast and cervical cancer. The service has two main purposes: Firstly, an effort to diagnose breast and cervical cancer at early stages, and secondly an emphasis is placed on preventing active cancer in these organs by detection in a precancerous stage. Our screening does not offer protection from other types of cancer.





ICELANDIC CANCER SOCIETY BREAST AND CERVICAL CANCER ORGANISERS

Region	Period	Region Counties		Mammogr aphy tests		Referral Hospital
Centre	1990/2015	78	78	1,600,261	57,664	6995
South	1997/2015	98	77	606,315	13,683	3126
North	1999/2015	86	75	884,310	58,689	5488
LPCC BCS	1990/2015	262	230	3,090,886	130,036	15,609


PORTUGUESE LEAGUE AGAINST CANCER

MAMMOGRAPHY MOBILE UNIT PORTUGAL


Q:WHAT IS THE **ROLE** IN REGARDS OF CANCER SCREENING PROGRAMMES OF YOUR ORGANISATION? (OPEN TEXT)

Q: AREAS OF INTEREST FOR STRUCTURED COOPERATION

- We initiated the above two screening projects
- For Colorectal Cancer Screening working in liaison with Ministry of Health aiming to go national
- For the three we inform, we don't promote. But we hope that promotion is done through informing
- We focus on providing balanced information on benefits and risks of cancer screening
- Research and evidence-based policy implementation promoter and organiser
- ORGANISER occasionally Prostate Cancer Screening & Melanoma Screening; PROMOTER sometimes ORGANISER Oral Cancer Screening



Stakeholders meetings




CHALLENGES

PROMOTION OF PRACTICE NOT YET RECOMMENDED BY EU GUIDELINES &




DEBATE OVER EFFECTIVENESS OF RECOMMENDED PRACTICE

SHARED AGENDA WITH EUROMED



Estimated age-standardized incidence rates (World) in 2018, cervix uteri, all ages




All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization / International Agency for Research on Cancer concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate borderlines for which there may not yet be full agreement.

Data source: GLOBOCAN 2018 Graph production: IARC (http://gco.iarc.fr/today) World Health Organization



Estimated age-standardized mortality rates (World) in 2018, cervix uteri, all ages



All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization / International Agency for Research on Cancer concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate borderlines for which there may not yet be full agreement.


Data source: GLOBOCAN 2018 Graph production: IARC (http://gco.iarc.fr/today) World Health Organization





GLOBAL MARKET STUDY HPV

FIG. 3: DEMAND-SUPPLY BALANCE OVER TIME¹³



13 Base case - Brazil, Argentina, China, and India excluded

QUICK STATS

NUMBER OF VACCINE SUBTYPES¹ 3

TOTAL NUMBER OF MANUFACTURERS²

2

2018 ESTIMATED GLOBAL SUPPLY

~30 million doses (maximum)

2018 ESTIMATED GLOBAL DEMAND

~30 million doses (supply constrained)

2017 REPORTED PRICE PER DOSE (RANGE) US \$4.50-\$154.28

BEATING CANCER: MISSION POSSIBLE


TOWARDS EFFECTIVE CANCER CONTROL IN EUROPE

MEPs Against Cancer

I. PREVENTION AS A KEY TO SUSTAINABLE CANCER CONTROL II. BEATING CANCER WITH HIGH QUALITY TREATMENTS III. IMPROVING CARE AND INVOLVING PATIENTS IN HEALTH POLICY DECISIONS

Promote access to quality assured cancer screening and early detection services, supporting Member States in the implementation of cancer screening guidelines and working with the WHO towards the elimination of cervical cancer;

SEE YOUR DOCTOR IF YOU HAVE






THE 7 SIGNS OF CANCER

INFORMATION PROVISION : EARLY DETECTION


- Irish Cancer Socie
- Launched August 2
- http://hpvalliance.i
- 41 members




ADDRESSING VACCINE CONFIDENCE

COOPERATION

BRIEF ASSESSMENT






EVIDENCE-BASED ADVOCACY; PRAGMATIC ADAPTATION ...



STAKEHOLDER ENGAGEMENT METHODS



FACILITATING INFORMED/SHARED DECISION MAKING



FUTURE CANCER SCREENING MEETING

WORLD CANCER CONGRESS 2020 – 19-22 OCTOBER, OMAN

Session workshop proposal?





THANK YOU!



nirr	nirringrazzjak		dziękuję ďa		kujem	
1.1.	hvala	danl	k u	danke	e mulțumesc	
paldies	aitäh	köszönöm		merci	obrigado	
graz	ie tak	kiitos	efharisto		5	
		ačiū				